Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Autonomous & Electric Vehicles (DRIV) vs Eli Lilly And Co (LLY) Price & Performance

Global X Autonomous & Electric VehiclesTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Global X Autonomous & Electric Vehicles vs Eli Lilly And Co — how do they compare? Global X Autonomous & Electric Vehicles trades at $36.09, while Eli Lilly And Co trades at $1,145.69 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while Global X Autonomous & Electric Vehicles pays none. Which is the better fit depends on your goals.

DRIVLLY
Sector
Sector/ThematicHealth
52-Week High
$42.53$1.24K
52-Week Low
$23.67$625.65
Market Cap
$1.03T
Enterprise Value
$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Autonomous & Electric Vehicles

DRIV trades at $35.37, down 3.2% on the day amid a bearish technical signal. The stock faces selling pressure with moving averages indicating a downtrend, though oversold RSI levels suggest potential near-term support. Recent news highlights strong global EV sales growth and China's aggressive expansion, providing a favorable industry backdrop for this electric vehicle-focused ETF.

The outlook remains cautious due to technical weakness, though industry momentum from rising EV adoption offers long-term growth potential. Key risks include regulatory uncertainty around Chinese vehicles and potential tariff impacts. Investors should monitor technical levels for stabilization signs amid volatile market conditions.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Autonomous & Electric Vehicles

DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.

Read more on DRIV

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY